Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00913744 · ClinicalTrials.gov registry record · Phase 2
Safety and Efficacy Study of Intravitreal Ocriplasmin in Subjects With AMD With Focal Vitreomacular Adhesion
A Phase 2 study, sponsored by ThromboGenics.
- Completed
- Registry status
- Phase 2
- Development phase
- 100
- Enrollment target
NCT00913744: Completed Phase 2 study, sponsored by ThromboGenics.
NCT00913744 is a Phase 2 study that has completed, run by ThromboGenics. The registered enrollment target is 100 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (25% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00913744, a Phase 2 study, has completed, sponsored by ThromboGenics.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 100 participants
- Enrollment target
Study Summary
This study will evaluate the safety and efficacy of Ocriplasmin intravitreal injection, in subjects diagnosed with exudative AMD with focal vitreomacular adhesion. Ultimately, it is believed that intravitreal ocriplasmin may offer physicians a safe agent for pharmacologic vitreolysis and nonsurgical resolution of focal vitreomacular adhesion in AMD subjects where this adhesion may be causally associated with worse prognosis).
Primary Outcome
The VMA release was determined by masked Central Reading Center Optical Coherence Tomography (OCT) evaluation
Interventions
- DRUG Sham injection
- DRUG Ocriplasmin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 100 participants |
| Start Date | 2010-01 |
| Est. Completion | 2013-04 |
| Phase | Phase 2 |
What the finished NCT00913744 record still lists
NCT00913744 is an interventional study that assigns participants to a tested intervention. The registered 100 participants enrollment target is mid-sized for trials with a published cap, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (25% lower).
The record links to 0 conditions, and to 2 interventions - of which Sham injection is the first listed.
NCT00913744 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00913744 about?
NCT00913744 is a clinical study titled "Safety and Efficacy Study of Intravitreal Ocriplasmin in Subjects With AMD With Focal Vitreomacular Adhesion". This study will evaluate the safety and efficacy of Ocriplasmin intravitreal injection, in subjects diagnosed with exudative AMD with focal vitreomacular adhesion. Ultimately, it is believed that intravitreal ocriplasmin may offer physicians a safe agent for pharmacologic vitreolysis and nonsurgical...
What is the current status of trial NCT00913744?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 100 participants. The study started on 2010-01. Estimated completion is 2013-04.
What interventions are being tested in trial NCT00913744?
The interventions under investigation include: Sham injection (DRUG), Ocriplasmin (DRUG).
Who is sponsoring clinical trial NCT00913744?
This trial is sponsored by ThromboGenics, which has 12 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00913744's enrollment target sits among peer trials
100 672nd of 2000 higher than 1,263 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01048281 · 100 participants
Clinical & Pathological Studies of Upper Gastrointestinal Carcinoma
- NCT01161199 · 100 participants
The Use of Leukapheresis to Support HIV Pathogenesis Studies
- NCT01327690 · 100 participants · Early Phase 1
Mental Health in Veterans and Families After Group Therapies
- NCT01730781 · 100 participants
Imaging Cannabinoid Receptors Using Positron Emission Tomography (PET) Scanning
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia